Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems.

Autor: Koleva-Kolarova R; Health Economics Research Centre, University of Oxford, Oxford, UK., Vellekoop H; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands., Huygens S; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands., Versteegh M; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands., Mölken MR; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands., Szilberhorn L; Syreon Research Institute, Budapest, Hungary.; Eötvös Loránd University, Budapest, Hungary., Zelei T; Syreon Research Institute, Budapest, Hungary., Nagy B; Syreon Research Institute, Budapest, Hungary., Wordsworth S; Health Economics Research Centre, University of Oxford, Oxford, UK.; National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK., Tsiachristas A; Health Economics Research Centre, University of Oxford, Oxford, UK.; National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK.
Jazyk: angličtina
Zdroj: Personalized medicine [Per Med] 2023 Jul; Vol. 20 (4), pp. 357-374. Date of Electronic Publication: 2023 Aug 14.
DOI: 10.2217/pme-2022-0133
Abstrakt: The cost-effectiveness and budget impact of introducing extended DPYD testing prior to fluoropyrimidine-based chemotherapy in metastatic breast cancer patients in the UK, The Netherlands and Hungary were examined. DPYD testing with ToxNav © was cost-effective in all three countries. In the UK and The Netherlands, the ToxNav strategy led to more quality-adjusted life years and fewer costs to the health systems compared with no genetic testing and standard dosing of capecitabine/5-fluorouracil. In Hungary, the ToxNav strategy produced more quality-adjusted life years at a higher cost compared with no testing and standard dose. The ToxNav strategy was found to offer budget savings in the UK and in The Netherlands, while in Hungary it resulted in additional budget costs.
Databáze: MEDLINE